Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma
CONCLUSION: Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.PMID:38657575 | DOI:10.1159/000539066 (Source: Acta Haematologica)
Source: Acta Haematologica - April 24, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research
Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma
CONCLUSION: Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.PMID:38657575 | DOI:10.1159/000539066 (Source: Acta Haematologica)
Source: Acta Haematologica - April 24, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research
Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma
CONCLUSION: Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.PMID:38657575 | DOI:10.1159/000539066 (Source: Acta Haematologica)
Source: Acta Haematologica - April 24, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research
Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma
CONCLUSION: Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.PMID:38657575 | DOI:10.1159/000539066 (Source: Acta Haematologica)
Source: Acta Haematologica - April 24, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research
Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma
CONCLUSION: Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.PMID:38657575 | DOI:10.1159/000539066 (Source: Acta Haematologica)
Source: Acta Haematologica - April 24, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research
Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma
CONCLUSION: Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.PMID:38657575 | DOI:10.1159/000539066 (Source: Acta Haematologica)
Source: Acta Haematologica - April 24, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research
Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma
CONCLUSION: Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.PMID:38657575 | DOI:10.1159/000539066 (Source: Acta Haematologica)
Source: Acta Haematologica - April 24, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research
Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma
CONCLUSION: Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.PMID:38657575 | DOI:10.1159/000539066 (Source: Acta Haematologica)
Source: Acta Haematologica - April 24, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research
A hematoma in the anterior abdominal muscle in a woman receiving venlafaxine. A literature review of the reports on similar cases
CONCLUSION: Given the cases of either reductions in the platelet count or impairment of platelet activity accompanied by bleeding events, every clinician should be aware of these possible adverse effects when prescribing SNRIs.PMID:38631301 | DOI:10.1159/000538652 (Source: Acta Haematologica)
Source: Acta Haematologica - April 17, 2024 Category: Hematology Authors: Chrysoula Boutari Evangelia Zarkada Athanasios Vyzantiadis Efthymia Vlachaki Genovefa Mantzou Cristine Karipidou Stamatia Theodoridou Source Type: research
A hematoma in the anterior abdominal muscle in a woman receiving venlafaxine. A literature review of the reports on similar cases
CONCLUSION: Given the cases of either reductions in the platelet count or impairment of platelet activity accompanied by bleeding events, every clinician should be aware of these possible adverse effects when prescribing SNRIs.PMID:38631301 | DOI:10.1159/000538652 (Source: Acta Haematologica)
Source: Acta Haematologica - April 17, 2024 Category: Hematology Authors: Chrysoula Boutari Evangelia Zarkada Athanasios Vyzantiadis Efthymia Vlachaki Genovefa Mantzou Cristine Karipidou Stamatia Theodoridou Source Type: research
A hematoma in the anterior abdominal muscle in a woman receiving venlafaxine. A literature review of the reports on similar cases
CONCLUSION: Given the cases of either reductions in the platelet count or impairment of platelet activity accompanied by bleeding events, every clinician should be aware of these possible adverse effects when prescribing SNRIs.PMID:38631301 | DOI:10.1159/000538652 (Source: Acta Haematologica)
Source: Acta Haematologica - April 17, 2024 Category: Hematology Authors: Chrysoula Boutari Evangelia Zarkada Athanasios Vyzantiadis Efthymia Vlachaki Genovefa Mantzou Cristine Karipidou Stamatia Theodoridou Source Type: research
Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria
CONCLUSION: Biological characteristics displayed greater aggressiveness in patients with positive CPC, leading to significantly shorter PFS and OS. The presence of CPC, ASCT, and overall response rate were independent prognostic factors. While no new threshold for pPCL with CPCs is proposed, but Myc rearrangements and CPC positivity could serve as ultra-high-risk factors for multiple myeloma.PMID:38626745 | DOI:10.1159/000538658 (Source: Acta Haematologica)
Source: Acta Haematologica - April 16, 2024 Category: Hematology Authors: Xianghong Jin Xianyong Jiang Hui Li Kaini Shen Shuangjiao Liu Miao Chen Chen Yang Bing Han Junling Zhuang Source Type: research
Efficacy, Safety and Quality of Life of Pegcetacoplan in Japanese Patients With Paroxysmal Nocturnal Hemoglobinuria Treated Within the Phase 3 PEGASUS Trial
CONCLUSION: These data suggest that Japanese patients with PNH can be effectively and safely managed with pegcetacoplan.CLINICALTRIALS: gov identifier: NCT03500549.PMID:38615657 | DOI:10.1159/000537696 (Source: Acta Haematologica)
Source: Acta Haematologica - April 14, 2024 Category: Hematology Authors: Hisakazu Nishimori Hideyuki Nakazawa Shinobu Tamura Toshiki Uchida Kensuke Usuki Johan Szamosi R égis Peffault de Latour Alexander R öth Jens Panse Source Type: research
Efficacy, Safety and Quality of Life of Pegcetacoplan in Japanese Patients With Paroxysmal Nocturnal Hemoglobinuria Treated Within the Phase 3 PEGASUS Trial
CONCLUSION: These data suggest that Japanese patients with PNH can be effectively and safely managed with pegcetacoplan.CLINICALTRIALS: gov identifier: NCT03500549.PMID:38615657 | DOI:10.1159/000537696 (Source: Acta Haematologica)
Source: Acta Haematologica - April 14, 2024 Category: Hematology Authors: Hisakazu Nishimori Hideyuki Nakazawa Shinobu Tamura Toshiki Uchida Kensuke Usuki Johan Szamosi R égis Peffault de Latour Alexander R öth Jens Panse Source Type: research
Long-term efficacy and safety of damoctocog alfa pegol prophylaxis in patients with haemophilia A aged 12- & lt;18 years at enrolment into PROTECT VIII
Conclusion Efficacy and safety of damoctocog alfa pegol was confirmed in adolescent patients with haemophilia A, with data for up to 6 years supporting its use as a long-term treatment option in this group as they transition into adulthood.PMID:38599195 | DOI:10.1159/000538702 (Source: Acta Haematologica)
Source: Acta Haematologica - April 10, 2024 Category: Hematology Authors: Mark T Reding Mindy Simpson Jonathan Ducore P ål Andrè Holme Monika Maas Enriquez Maria Elisa Mancuso Source Type: research
